Has Christopher Neville, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,477 in general payments to Christopher Neville, MD across 65 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Christopher Neville, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Christopher Neville, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Christopher Neville, MD

Radiation Oncology · Modesto, CANPI 1790743136

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,022 of the $7,477 with a category attached, or 80.5%. It is spread thinly across 27 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,052 and has fallen 83.4% since, to $340 in 2025.

$7,477in general payments, 2019–2025

Across 65 payments — averaging $115.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$883
Bioprotect Medical, Inc.$835
Amgen$721
Gilead$627
GT Medical Technologies, Inc$574
AstraZeneca$540
plus $3K from 21 others

What the payments were for

Travel & lodging$1,45519%
Food & beverage$6,02281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	5	$883
Bioprotect Medical, Inc.	3	$835
Amgen	7	$721
Gilead(2 entities)	6	$627
GT Medical Technologies, Inc	6	$574
AstraZeneca(2 entities)	5	$540
Siemens Medical Solutions USA, Inc.	4	$450
Eisai Inc.	3	$338
Brainlab, Inc.	1	$234
Johnson & Johnson	2	$229
Merck	2	$215
E.r. Squibb & Sons, L.L.C.	2	$190
Lilly USA, LLC	2	$187
Pfizer	2	$181
Seagen Inc.	2	$178
Zap Surgical Systems, Inc.	1	$154
GSK	1	$125
Daiichi Sankyo Inc.	1	$111
Stemline Therapeutics Inc.	1	$111
Genentech USA, Inc.	1	$107
Tesaro, Inc.	1	$105
Rigel Pharmaceuticals, Inc.	1	$101
Regeneron Healthcare Solutions, Inc.	1	$98
Focal Therapeutics, Inc.	1	$72
Advanced Accelerator Applications	1	$57
Teleflex LLC	2	$41
Tactile Systems Technology Inc	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,477 in reported general payments places this provider in the 85th percentile of 627 radiation oncology providers in California.

See all radiation oncology providers in California →

Medicare billing

Part B allowed, 2024

$201,639

Medicare patients

217

Services billed

2,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tamsulosin Hcl	21	$175

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Modesto

Rakesh PatelLos Gatos$1.3M
Amir LavafPalm Springs$411K
Albert ChangLos Angeles$290K
Arya AminiDuarte$265K
Rizwan NuraniApple Valley$220K
Drew MoghanakiLos Angeles$183K
Jyoti MayadevSan Diego$170K
Percy LeeIrvine$125K
Felix FengSan Francisco$99K
Hyun KimDuarte$97K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →